Last update Aug. 6, 2017
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Miglitol belongs to this group or family:
Main tradenames from several countries containing Miglitol in its composition:
|Oral Bioavail.||50 - 70||%|
|Protein Binding||< 4||%|
|Tmax||2 - 3||hours|
|T½||2 - 3||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Alpha-glucosidase inhibitor which acts within the gastrointestinal tract without being absorbed, reducing intestinal absorption of glucose. Very low risk of hypoglycemia in monotherapy.
Miglitol is excreted in breast milk in minute quantities (Serrano 2014, Pfizer 2012, AEMPS 2009) reaching a relative dose much less than 1%.
Diet, exercise, and breastfeeding improve blood sugar levels.
See below the information of this related product: